FierceBiotechGilead backs $60M Hookipa round to fund immunotherapy R&DFierceBiotechGilead backs $60M Hookipa round to fund immunotherapy R&D. by Nick Paul Taylor |. Dec 11, 2017 8:11am. gilead4. Hookipa is developing a pipeline derived from two… Continue reading
Synthetic Biology Market Set for 19.9% CAGR Explosive Growth to 2022 Led by Genome Engineering Technology …PR Newswire (press release)While the US is expected to hold the largest share of the global synthetic biology market in 2017, China is expected… Continue reading
Synthetic Biology Market Set for 19.9% CAGR Explosive Growth to 2022 Led by Genome Engineering Technology …PR Newswire (press release)While the US is expected to hold the largest share of the global synthetic biology market in 2017, China is expected… Continue reading
Labiotech.eu (blog) |
Off-the-Shelf CAR–T Cells Struggle to Improve Cancer Treatment
Labiotech.eu (blog) Data presented at ASH 2017 shows that Servier and Pfizer’s UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR–T cells. CAR–T cell therapy has proved to be effective at treating cancer in … |